Why Your Doctor May or May Not Prescribe Ivermectin: A Patient's Guide to the Clinical Decision Process

For many Americans, the experience of requesting ivermectin from a physician can feel unpredictable. One provider writes the prescription without hesitation; another declines entirely. The difference rarely comes down to personal preference alone. Instead, it reflects a layered clinical framework that weighs approved indications, patient-specific risk factors, and evolving medical guidance. Understanding that framework can help patients enter the conversation better informed — and better prepared.

What the FDA Has Actually Approved

Any discussion of ivermectin prescribing must begin with what the Food and Drug Administration has formally sanctioned. In the United States, ivermectin carries FDA approval for two primary human indications: intestinal strongyloidiasis (an infection caused by the roundworm Strongyloides stercoralis) and onchocerciasis (also known as river blindness, caused by Onchocerca volvulus). The oral tablet formulation is also approved for treating head lice and certain skin conditions, including rosacea, through a topical cream form.

When a physician receives a request that falls squarely within these approved uses — say, a patient presenting with confirmed strongyloidiasis following travel to a region where the parasite is endemic — the prescribing calculus is relatively straightforward. The drug has an established safety and efficacy profile for that condition, and the clinical pathway is well-defined.

Outside of these indications, however, the terrain becomes considerably more complex.

Off-Label Prescribing: Legal but Scrutinized

Physicians in the United States retain the legal authority to prescribe any approved medication for uses not specifically listed on its label. This practice — known as off-label prescribing — is common across virtually every medical specialty and accounts for a meaningful portion of all prescriptions written annually.

For ivermectin, off-label interest surged significantly during the COVID-19 pandemic, prompting a wave of requests that many physicians were unprepared to navigate. Major health bodies, including the FDA, the Centers for Disease Control and Prevention, and the National Institutes of Health, issued guidance advising against its use for COVID-19 outside of clinical trials, citing insufficient evidence of benefit and documented risks associated with unsupervised use.

This institutional guidance did not eliminate off-label prescribing — it never could, legally — but it did create a professional environment in which many physicians became more cautious. A doctor who writes an off-label prescription against the recommendations of major medical bodies assumes a degree of professional and liability exposure that not every provider is willing to accept. That calculus, more than any individual opinion about the drug itself, explains much of the variation patients encounter.

How Physicians Evaluate Patient Candidacy

For approved indications, the clinical evaluation process typically involves several distinct steps.

Confirming the diagnosis. A physician will generally want objective evidence of the condition being treated. For parasitic infections, this may mean stool testing, skin snip biopsies, or serological assays depending on the suspected organism. Arriving at an appointment with documentation of prior testing, travel history, or specialist referrals strengthens the case for a prescription.

Reviewing the patient's medication list. Ivermectin interacts with several drug classes, most notably anticoagulants and certain medications that affect the central nervous system. Physicians will assess whether any existing prescriptions create a contraindication or require dosage adjustment. Patients should arrive prepared to provide a complete and current medication list, including over-the-counter supplements.

Assessing weight and renal or hepatic function. Ivermectin dosing is weight-based, and patients with compromised liver or kidney function may require modified approaches. Physicians treating patients with these comorbidities will factor organ function into both the decision to prescribe and the specific regimen selected.

Evaluating pregnancy and nursing status. The drug is classified as Pregnancy Category C, meaning animal studies have shown potential fetal risk and there are no adequate human studies. Most physicians will decline to prescribe it to pregnant patients outside of circumstances where the benefit clearly outweighs the risk. Nursing mothers are similarly advised to exercise caution.

Common Reasons for Prescription Denials

Patients who leave a provider's office without a prescription often receive one of a handful of explanations. Understanding these reasons can help clarify whether an alternative pathway — such as a second opinion or a telehealth consultation — is worth pursuing.

No confirmed diagnosis. If a physician cannot verify the condition the patient believes they have, they are unlikely to prescribe a medication with real side effect potential. Requesting a referral for diagnostic testing before scheduling a prescription-focused appointment can address this barrier.

Request falls outside approved indications. Some physicians are simply unwilling to prescribe for uses that lack FDA approval, particularly in the current regulatory climate. This is a professional judgment call, not a legal prohibition, and patients retain the option of seeking a second opinion.

Contraindicated by existing conditions or medications. In some cases, a denial reflects a genuine safety concern specific to the individual patient. This type of refusal warrants a direct conversation about what the contraindication is and whether it can be managed.

Institutional or practice-level policies. Physicians employed by large health systems or hospital networks sometimes operate under prescribing policies that restrict off-label use of specific medications. Individual providers within these systems may not have the discretion to override those policies even if they personally find the request reasonable.

What Patients Can Do Before the Appointment

Preparing thoroughly before meeting with a provider can meaningfully improve the outcome of the conversation.

First, document symptoms carefully and gather any relevant diagnostic records. A well-organized medical history signals that the request is grounded in clinical need rather than general curiosity or self-diagnosis.

Second, research the specific approved indication most relevant to your situation. Understanding the clinical language your physician uses — and demonstrating familiarity with the condition you believe you have — facilitates a more productive dialogue.

Third, be transparent about all medications and supplements currently in use. Physicians are more likely to engage constructively when they can complete a full risk assessment rather than working with incomplete information.

Finally, consider whether a telehealth provider with documented experience prescribing ivermectin for your specific condition might be an appropriate avenue if your primary care physician is not the right fit for this particular request. Telemedicine has expanded access to specialist consultations significantly, and several platforms now connect patients with licensed providers who are well-versed in the clinical literature surrounding this drug.

The Physician's Perspective

It is worth acknowledging that the variability patients experience is not arbitrary. Physicians navigate a genuine tension between patient autonomy, evidence-based practice, institutional expectations, and their own professional judgment. A provider who declines to prescribe ivermectin for a use case they find clinically unsupported is not necessarily dismissing the patient's concerns — they are exercising the same caution they would apply to any medication with a contested evidence base.

Patients who approach the conversation with that understanding — rather than framing the request as a test of the physician's openness — are generally more likely to receive a thorough and respectful evaluation, regardless of how it concludes.

Moving Forward with Accurate Expectations

The ivermectin prescribing landscape in the United States is neither uniformly permissive nor uniformly restrictive. It is, instead, a reflection of the same individualized clinical judgment that governs every prescription medication. Patients who understand the criteria physicians apply, prepare accordingly, and engage honestly with their providers are best positioned to navigate that process — whether the outcome is a prescription, a referral, or a conversation about alternative approaches.